Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $60.22 Average Target Price from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $60.22.

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price on the stock.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors have recently bought and sold shares of the business. KBC Group NV increased its position in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares during the last quarter. Invesco Ltd. grew its position in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock valued at $1,064,000 after purchasing an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the last quarter. Swiss National Bank grew its position in shares of Celldex Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock valued at $2,964,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of Celldex Therapeutics by 5.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after purchasing an additional 2,070 shares during the last quarter.

Celldex Therapeutics Stock Performance

CLDX opened at $22.46 on Friday. Celldex Therapeutics has a 52-week low of $20.91 and a 52-week high of $53.18. The firm has a market capitalization of $1.49 billion, a PE ratio of -8.74 and a beta of 1.60. The business’s 50-day simple moving average is $24.33 and its 200 day simple moving average is $29.37.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.